Cargando…

Non-alcoholic fatty liver disease is associated with dysregulated bile acid synthesis and diarrhea: A prospective observational study

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) may be associated with changes in bile acid (BA) metabolism. Hepatic BA production, measured by serum levels of the precursor 7α-hydroxy-4-cholesten-3-one (C4), is regulated by the farnesoid-X-receptor (FXR)-dependent ileal hormone fibroblast gro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Appleby, Richard N., Moghul, Iman, Khan, Shahid, Yee, Michael, Manousou, Pinelope, Neal, Tracy Dew, Walters, Julian R. F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6347262/ https://www.ncbi.nlm.nih.gov/pubmed/30682184 http://dx.doi.org/10.1371/journal.pone.0211348

Ejemplares similares

Fibroblast Growth Factor 19 and 7α-Hydroxy-4-Cholesten-3-one in the Diagnosis of Patients With Possible Bile Acid Diarrhea
por: Pattni, Sanjeev S, et al.
Publicado: (2012)

Novel associations of bile acid diarrhoea with fatty liver disease and gallstones: a cohort retrospective analysis
por: Appleby, Richard N, et al.
Publicado: (2017)

Potent stimulation of fibroblast growth factor 19 expression in the human ileum by bile acids
por: Zhang, Justine H., et al.
Publicado: (2013)

Canadian Association of Gastroenterology Clinical Practice Guideline on the Management of Bile Acid Diarrhea
por: Sadowski, Daniel C, et al.
Publicado: (2019)

Bile Acids and Dysbiosis in Non-Alcoholic Fatty Liver Disease
por: Mouzaki, Marialena, et al.
Publicado: (2016)

Bile acids and sphingolipids in non-alcoholic fatty liver disease
por: Jackson, Kaitlyn G., et al.
Publicado: (2022)

Metabolic Profile Reflects Stages of Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease
por: Jambulingam, Nila, et al.
Publicado: (2023)

Bile Acid Diarrhea: Prevalence, Pathogenesis, and Therapy
por: Camilleri, Michael
Publicado: (2015)

Pathophysiology and Clinical Management of Bile Acid Diarrhea
por: Marasco, Giovanni, et al.
Publicado: (2022)

Non-alcoholic fatty liver disease in women – Current knowledge and emerging concepts
por: Eng, Pei Chia, et al.
Publicado: (2023)

Applying Lipidomics to Non-Alcoholic Fatty Liver Disease: A Clinical Perspective
por: Huang, Jian, et al.
Publicado: (2023)

Gut Microbiota—A Future Therapeutic Target for People with Non-Alcoholic Fatty Liver Disease: A Systematic Review
por: Forlano, Roberta, et al.
Publicado: (2022)

Circadian Dysregulation Disrupts Bile Acid Homeostasis
por: Ma, Ke, et al.
Publicado: (2009)

The Intestinal Barrier and Its Dysfunction in Patients with Metabolic Diseases and Non-Alcoholic Fatty Liver Disease
por: Forlano, Roberta, et al.
Publicado: (2022)

Bile Acid Diarrhea and NAFLD: Shared Pathways for Distinct Phenotypes
por: Weaver, Michael J., et al.
Publicado: (2020)

Targeting the ileal bile salt transporter in the treatment of non-alcoholic fatty liver disease
por: Jansen, Peter L. M.
Publicado: (2021)

Dysregulated RNA polyadenylation contributes to metabolic impairment in non-alcoholic fatty liver disease
por: Jobbins, Andrew M, et al.
Publicado: (2022)

Diacylglycerol acyltransferase 1/2 inhibition induces dysregulation of fatty acid metabolism and leads to intestinal barrier failure and diarrhea in mice
por: Takemoto, Kosuke, et al.
Publicado: (2020)

Gut Microbiota-Bile Acid Crosstalk in Diarrhea-Irritable Bowel Syndrome
por: Zhan, Kai, et al.
Publicado: (2020)

Why Bile Acids Are So Important in Non-Alcoholic Fatty Liver Disease (NAFLD) Progression
por: Gottlieb, Aline, et al.
Publicado: (2019)

The Role of Gut Microbiota-Bile Acids Axis in the Progression of Non-alcoholic Fatty Liver Disease
por: Ni, Yiming, et al.
Publicado: (2022)

Proteomic identification and characterization of hepatic glyoxalase 1 dysregulation in non-alcoholic fatty liver disease
por: Spanos, Christos, et al.
Publicado: (2018)

Liver injury in non-alcoholic fatty liver disease is associated with urea cycle enzyme dysregulation
por: Gallego-Durán, Rocío, et al.
Publicado: (2022)

L-arginine conjugates of bile acids-a possible treatment for non-alcoholic fatty liver disease
por: Voloshin, Irina, et al.
Publicado: (2014)

Biological tuners to reshape the bile acid pool for therapeutic purposes in non-alcoholic fatty liver disease
por: Gillard, Justine, et al.
Publicado: (2023)

The Crosstalk between Gut Microbiota and Bile Acids Promotes the Development of Non-Alcoholic Fatty Liver Disease
por: Li, Zhonglin, et al.
Publicado: (2023)

Dysregulation of bile acids increases the risk for preterm birth in pregnant women
por: You, Sangmin, et al.
Publicado: (2020)

Role of Bile Acids in the Regulation of Food Intake, and Their Dysregulation in Metabolic Disease
por: Xie, Cong, et al.
Publicado: (2021)

Bile Acid Dysregulation Is Intrinsically Related to Cachexia in Tumor-Bearing Mice
por: Thibaut, Morgane M., et al.
Publicado: (2021)

Managing Chronic Diarrhea From a Gut Microbiota-Bile Acid Perspective
por: Zhao, Ling, et al.
Publicado: (2020)

A case of COVID-19 diarrhea relieved by bile acid sequestrant administration
por: Shirohata, Akira, et al.
Publicado: (2022)

Serum Metabolomic Profiling in Acute Alcoholic Hepatitis Identifies Multiple Dysregulated Pathways
por: Rachakonda, Vikrant, et al.
Publicado: (2014)

Acute steatohepatitis, due to extreme metabolic dysregulation, as the first presentation of non-alcoholic fatty liver disease
por: Kranidiotis, Georgios, et al.
Publicado: (2013)

Correction to: Proteomic identification and characterization of hepatic glyoxalase 1 dysregulation in non-alcoholic fatty liver disease
por: Spanos, Christos, et al.
Publicado: (2018)

A network-based approach reveals the dysregulated transcriptional regulation in non-alcoholic fatty liver disease
por: Yang, Hong, et al.
Publicado: (2021)

Dysregulation of GABAergic Signalling Contributes in the Pathogenesis of Diarrhea-predominant Irritable Bowel Syndrome
por: Aggarwal, Surbhi, et al.
Publicado: (2018)

Non-Alcoholic Fatty Liver Disease: The Bile Acid-Activated Farnesoid X Receptor as an Emerging Treatment Target
por: Fuchs, Michael
Publicado: (2012)

The Associations between Circulating Bile Acids and the Muscle Volume in Patients with Non-alcoholic Fatty Liver Disease (NAFLD)
por: Kobayashi, Yoshinao, et al.
Publicado: (2017)

Hyperoside attenuates non-alcoholic fatty liver disease in rats via cholesterol metabolism and bile acid metabolism
por: Wang, Songsong, et al.
Publicado: (2021)

Derivation and validation of a cardiovascular risk score for prediction of major acute cardiovascular events in non‐alcoholic fatty liver disease; the importance of an elevated mean platelet volume
por: Abeles, Robin D., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_79fbojnollj37g0ean7qpgi4lo